/
Oncology
Metastatic Breast Cancer
55
Pipeline Programs↗
51
Active Trials↗
24
Companies Involved↗
Metastatic Breast Cancer is a moderately active landscape with 55 programs across 24 companies. The most active players are Roche, Merck & Co., Boehringer Ingelheim. 21 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 14
Phase 211
Phase 321
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
37 of 50 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 91% of 55 pipeline programs.
Analysis
Trial Status
59
clinical trials
Recruiting27 · 46%
Active, not recruiting20 · 34%
Completed5 · 8%
Not yet recruiting4 · 7%
Terminated3 · 5%
Clinical Trials
Trial Activity
59 trials
A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Recruiting·—·Phase 2·NCT05846789·168 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)